Skip to main content

Mates Sharon's Form 4 filing

Intra-Cellular Therapies, Inc.ITCI · filed Aug 23, 2024

Accession no.
0000950170-24-100275
Filed
Aug 23, 2024
Trade date
Aug 21-23, 2024
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 10 non-derivative transactions and 3 derivative transactions. Open-market sales total $9.09M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Mates SharonCIK 0001585699Director, Officer (Chairman and CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 21, 2024Common StockMOption exerciseAcquired+53,013$17.57+$931,438.411,123,342Direct
Aug 21, 2024Common StockSSaleDisposed−44,134$75.40F2−$3,327,703.61,079,208Direct
Aug 21, 2024Common StockSSaleDisposed−4,297$76.20F3−$327,431.41,074,911Direct
Aug 21, 2024Common StockSSaleDisposed−2,682$77.21F4−$207,077.221,072,229Direct
Aug 21, 2024Common StockSSaleDisposed−1,900$77.98F5−$148,1621,070,329Direct
Aug 22, 2024Common StockMOption exerciseAcquired+39,380$17.57+$691,906.61,109,709Direct
Aug 22, 2024Common StockSSaleDisposed−35,011$74.58F6−$2,611,120.381,074,698Direct
Aug 22, 2024Common StockSSaleDisposed−4,369$75.47F7−$329,728.431,070,329Direct
Aug 23, 2024Common StockMOption exerciseAcquired+28,680$17.57+$503,907.61,099,009Direct
Aug 23, 2024Common StockSSaleDisposed−28,680$74.46F8−$2,135,512.81,070,329Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 21, 2024Common StockMOption exerciseDisposed−53,013$0.00$0163,985Direct
Aug 22, 2024Common StockMOption exerciseDisposed−39,380$0.00$0124,605Direct
Aug 23, 2024Common StockMOption exerciseDisposed−28,680$0.00$095,925Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.90 to $75.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.90 to $76.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.975 to $77.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.905 to $78.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

F6

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.28 to $75.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

F7

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.30 to $75.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

F8

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.16 to $74.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

Remarks

EX-24.1 - Power of Attorney

Read the full filing on SEC EDGAR (opens in a new tab)